Market Overview

'Telehealth' Is Coming To The Mainstream In A Pure-Play Package

Share:
'Telehealth' Is Coming To The Mainstream In A Pure-Play Package
Related TDOC
15 Biggest Mid-Day Gainers For Thursday
Benzinga's Top Upgrades, Downgrades For May 18, 2017
Related CVS
Vaccine Business The Gateway To Drug Stores Providing Profitable Primary Healthcare
Amazon In The Pharmacy Space: Is There Anything To This Beyond The Headlines?
Empire Life Investments Inc. Buys JELD-WEN Holding Inc, Lowe's Inc, CVS Health Corp, Sells SPDR ... (GuruFocus)
  • Teladoc Inc (NYSE: TDOC) shares are down 22 percent over the past month, declining steadily since August 10.
  • Leerink Partners’ Steven Wardell initiated coverage of the company with an Outperform rating and a price target of $35.
  • Telehealth has made an entry into the mainstream, Wardell said, citing the reasons as healthcare cost inflation, provider shortages, and healthcare consumerism.

Analyst Steven Wardell said there was a shortage of physicians in the US. Due to this shortage, 62 million Americans had no or inadequate access to primary care, according to the National Association of Community Health Centers. “Telehealth can help address this shortage by making physicians more accessible and filling up their schedules more efficiently,” Wardell wrote.

Employers aiming to control costs are favoring Telehealth. Healthcare benefit costs are growing at a rate faster than inflation and continue to be a major concern area for employers.

Earlier this month, CVS Health Corp (NYSE: CVS) [rated Outperform] announced its plans to partner with Teladoc to offer a wider range of telehealth solutions to customers. “We believe this will generate new consumer demand for telehealth services and feed Teladoc additional volume over time,” Wardell commented.

Leerink Partners estimates the addressable market at over $17 billion for the ambulatory domain alone. Citing Teladoc as “one of the fastest growers in our Digital Health universe,” the analyst said that the company is poised for 60 percent top-line CAGR over the next three years.

Latest Ratings for TDOC

DateFirmActionFromTo
May 2017KeyBancInitiates Coverage OnOverweight
May 2017Craig-HallumDowngradesBuyHold
Apr 2017Cantor FitzgeraldDowngradesNeutral

View More Analyst Ratings for TDOC
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas Health Care Initiation Top Stories Analyst Ratings Trading Ideas Best of Benzinga

 

Related Articles (CVS + TDOC)

View Comments and Join the Discussion!